A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1 Antihistamines
Latest Information Update: 16 Feb 2026
At a glance
- Drugs Ozureprubart (Primary)
- Indications Chronic urticaria
- Focus Registrational; Therapeutic Use
Most Recent Events
- 11 Feb 2026 Status changed from planning to recruiting.
- 17 Nov 2025 New trial record
- 20 Oct 2025 According to RAPT Therapeutics media release, based on the positive results from phase II trial company is moving to a pivotal Phase 3 trial in CSU and plans to discuss next steps with the FDA and other regulatory authorities.